GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Advances Amgen's mission to serve patients with rare disease medicines
Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support
Subscribe To Our Newsletter & Stay Updated
